eISSN: 1731-2515
ISSN: 0209-1712
Anestezjologia Intensywna Terapia
Bieżący numer Archiwum O czasopiśmie Rada naukowa Recenzenci Prenumerata Kontakt Zasady publikacji prac
vol. 52
Poleć ten artykuł:
streszczenie artykułu:
List do Redakcji

Risk of propofol use for sedation in COVID-19 patients

Kenji Yamamoto

Department of Cardiovascular Surgery, Okamura Memorial Hospital, Shizuoka, Japan
Anestezjologia Intensywna Terapia 2020; 52, 4: 358–359
Data publikacji online: 2020/11/15
Pełna treść artykułu
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Dear Editor,
The spread of coronavirus disease (COVID-19) has led to an increasing number of severe cases, with many patients needing ventilation. In such cases, continuous sedation is required, and based on recent literature, ICU mortality is around 20–30% [1].
Sedatives currently used in clinical practice include midazolam, propofol, and dexmedetomidine. Propofol has several properties that make it a potentially superior choice for sedation of intubated ICU patients. Sedation with propofol can be rapidly commenced and terminated, even after prolonged administration, allowing for greater control over the level of sedation and faster weaning from mechanical ventilation. However, propofol has several drawbacks that should be considered, especially in COVID-19 patients.
In 2015, Schläpfer et al. [2] conducted a study using a rat sepsis model. They reported that all rats anaesthetised with propofol died within 24 hours, unlike those treated with other anaesthetics. If the infusion rate or the total dose is too high, intravenously infused lipid emulsions might inhibit the function of the reticuloendothelial system, resulting in immunosuppression [3]. Intravenously administered lipid emulsions bind to serum proteins, thereby forming lipoproteins. If the dose is too high, the fat droplets that do not form lipoproteins are treated by the body’s immune system as foreign substances and are phagocytosed by reticuloendothelial cells. This response might lead to a diminished immune reaction to other foreign substances such as bacteria and viruses.
When propofol was introduced in the United States, surgical-site infection (SSI) cases increased nationwide. In June 1990, the Centers for Disease Control and Prevention reported that propofol use increases the risk for SSIs because of bacterial contamination of lipid emulsions [4]. A recent study reported that the number of SSI cases in patients undergoing gastroenterological surgery was significantly higher with propofol use than with sevoflurane use. Therefore, it was concluded that surgical contamination was not the cause of the SSIs [5]. Following the switch in the treatment from inhaled sevoflurane anaesthesia to total intravenous propofol anaesthesia at our hospital, clinicians noticed a sudden and significant increase in the number of SSIs in patients who underwent open-heart surgery. After experiencing difficulties in infection control for 2–3 years, the results were presented at the...

Pełna treść artykułu...
facebook linkedin twitter
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe